Intravenous immunoglobulin in autoimmune and inflammatory diseases: More than mere transfer of antibodies

Transfusion and Apheresis Science

Volumn 37, Issue 1, 2007, Pages 103-107

  Sibéril, Sophie ^a,b,c   Elluru, SriRamulu ^a,b,c   Negi, Vir Singh ^d   Ephrem, Amal ^a,b,c   Misra, Namita ^a,b,c   Delignat, Sandrine ^a,b,c   Bayary, Jagadeesh ^a,b,c   Lacroix Desmazes, Sébastien ^a,b,c   Kazatchkine, Michel D ^a,b,c   Kaveri, Srini V ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Autoimmunity; Dendritic cell; Immune modulation; Inflammation; Intravenous immunoglobulin

Indexed keywords

ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; GUILLAIN BARRE SYNDROME; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; LYMPHOCYTE PROLIFERATION; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYASTHENIA GRAVIS; NONHUMAN; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOCYTOPENIA;

AUTOIMMUNE DISEASES; HOMEOSTASIS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFLAMMATION;

EID: 35348864403     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2007.01.012     Document Type: Article

References (42)

1. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 (2001) 747-755
2. Jolles S., Sewell W.A., and Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142 (2005) 1-11
3. Dalakas M.C. Sporadic inclusion body myositis-diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2 (2006) 437-447
4. Bayry J., Lacroix-Desmazes S., Kazatchkine M., and Kaveri S.V. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action. Nat Clin Pract Rheumatol 3 (2007) 262-272
5. Lacroix-Desmazes S., Kaveri S.V., Mouthon L., Ayouba A., Malanchere E., Coutinho A., et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 216 (1998) 117-137
6. Debre M., Bonnet M.C., Fridman W.H., Carosella E., Philippe N., Reinert P., et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 342 (1993) 945-949
7. Bussel J.B. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 37 (2000) 261-266
8. van Mirre E., Teeling J.L., van der Meer J.W., Bleeker W.K., and Hack C.E. Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcγRII and FcγRIIIb. J Immunol 173 (2004) 332-339
9. Kimberly R.P., Salmon J.E., Bussel J.B., Crow M.K., and Hilgartner M.W. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 132 (1984) 745-750
10. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
11. Kaneko Y., Nimmerjahn F., Madaio M.P., and Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789-797
12. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., and Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest 115 (2005) 2914-2923
13. Akilesh S., Petkova S., Sproule T.J., Shaffer D.J., Christianson G.J., and Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328-1333
14. Kazatchkine M.D., Dietrich G., Hurez V., Ronda N., Bellon B., Rossi F., et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 139 (1994) 79-107
15. Abedi M.R., Hammarstrom L., Broome U., Angelin B., Smith C.I., and Christensson B. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin Exp Immunol 105 (1996) 266-273
16. Vassilev T., Yamamoto M., Aissaoui A., Bonnin E., Berrih-Aknin S., Kazatchkine M.D., et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol 29 (1999) 2436-2442
17. Sami N., Bhol K.C., and Ahmed A.R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105 (2002) 192-198
18. Andersson U., Bjork L., Skansen S.U., and Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 139 (1994) 21-42
19. Andersson U.G., Bjork L., Skansen-Saphir U., and Andersson J.P. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79 (1993) 211-216
20. Ruiz de Souza V., Carreno M.P., Kaveri S.V., Ledur A., Sadeghi H., Cavaillon J.M., et al. Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 25 (1995) 1267-1273
21. Sharief M., Ingram D., Swash M., and Thompson E.I.V. Immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology 52 (1999) 1833-1838
22. Basta M., Fries L.F., and Frank M.M. High-dose intravenous immunoglobulin inhibits in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77 (1991) 376-380
23. Mollnes T.E., Hogasen K., De Carolis C., Vaquero E., Nielsen E.W., Fontana L., et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 48 (1998) 312-317
24. Lutz H.U., Stammler P., Jelezarova E., Nater M., and Spath P.J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 88 (1996) 184-193
25. Basta M., and Dalakas M.C. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complements fragments. J Clin Invest 94 (1994) 1729-1735
26. Lutz H.U., Stammler P., Bianchi V., Trueb R.M., Hunziker T., Burger R., et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103 (2004) 465-472
27. van Schaik I.N., Lundkvist I., Vermeulen M., and Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol 12 (1992) 325-334
28. van Schaik I.N., Vermeulen M., and Brand A. In vitro effects of polyvalent immunoglobulin for intravenous use. J Neurol Neurosurg Psychiatry 57 Suppl. 15-17 (1994)
29. Prasad N.K., Papoff G., Zeuner A., Bonnin E., Kazatchkine M.D., Ruberti G., et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161 (1998) 3781-3790
30. Altznauer F., von Gunten S., Spath P., and Simon H.U. Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 112 (2003) 1185-1190
31. Marchalonis J.J., Kaymaz H., Dedeoglu F., Schlutter S.F., Yocum D.E., and Edmundson A.B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor ß chain. Proc Natl Acad Sci USA 89 (1992) 3325-3329
32. Svenson M., Hansen M.B., Ross C., Diamant M., Rieneck K., Nielsen H., et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in Human IgG preparations. Blood 91 (1998) 2054-2061
33. Vassilev T., Gelin C., Kaveri S.V., Zilber M.T., Boumsell L., and Kazatchkine M.D. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 92 (1993) 369-372
34. Hurez V., Kaveri S.V., Mouhoub A., Dietrich G., Mani J.C., Klatzmann D., et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap Immunol 1 (1994) 269-278
35. Kaveri S., Vassilev T., Hurez V., Lengagne R., Cot S., Pouletty P., et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest 97 (1996) 865-869
36. Vassilev T., Kazatchkine M.D., Duong Van Huyen J.P., Mekrache M., Bonnin E., Korinth D., et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 93 (1999) 3624-3631
37. Bouhlal H., Hocini H., Quillent-Gregoire C., Donkova V., Rose S., Amara A., et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 166 (2001) 7606-7611
38. Bayry J., Lacroix-Desmazes S., Donkova-Petrini V., Carbonneil C., Misra N., Lepelletier Y., et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101 (2004) 14210-14215
39. de Grandmont M.J., Racine C., Roy A., Lemieux R., and Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 101 (2003) 3065-3073
40. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758-765
41. Bayry J., Lacroix-Desmazes S., Delignat S., Mouthon L., Weill B., Kazatchkine M.D., et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 3497-3502
42. Bayry J., Hermine O., Webster D.A., Levy Y., and Kaveri S.V. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med 11 (2005) 370-376